Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

The Motley Fool

14 Jun 2026, 15:14 UTC · 2h ago

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

What the story claims

3 claims · each scored for market impact

What matters in this story

1
UroGen Pharma settled with Teva Pharmaceuticals, granting Teva a non-exclusive license to sell generic Jelmyto starting September 15, 2030. — The loss of exclusivity for a product that constitutes over 40% of total revenue creates a defined future cliff for earnings.
-0.40
2
UroGen Pharma's Zusduri sales increased 109% year-over-year to $29.2 million in the first quarter. — Rapid growth in a secondary product helps diversify revenue and potentially offset future generic losses from Jelmyto.
+0.30
3
Chief Medical Officer Mark Schoenberg sold 5,222 ordinary shares for approximately $143,000. — While insider selling can be a bearish signal, the sale is small relative to his remaining holdings of nearly 140,000 shares.
-0.10

Which stocks this story touches

6 related stories

The Motley Fool
6h ago
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
- biotech
- pharmaceuticals
- sec filing
Read

Is UroGen Pharma a Stock… — TEVA +0.30 | NewsImpactScreener

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

What matters in this story

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

What matters in this story

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

EverCommerce's CEO Sells 19,200 Shares

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

ROSEN, A LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Nayax's CTO and Co-Founder Sold Nearly 30,000 Company Shares for $2.2 Million. Should Investors Worry?

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

What matters in this story

Next reads from the same story arc

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

What matters in this story

Next reads from the same story arc

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

EverCommerce's CEO Sells 19,200 Shares

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

ROSEN, A LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Nayax's CTO and Co-Founder Sold Nearly 30,000 Company Shares for $2.2 Million. Should Investors Worry?